Effect of High Dose Vitamin D Supplementation on HIV Latency
Status:
Completed
Trial end date:
2019-05-21
Target enrollment:
Participant gender:
Summary
HIV persists despite antiretroviral therapy (ART) and is associated with chronic
inflammation. This inflammation is thought to prevent an effective immune response against
the virus and is mediated at least in part by gut epithelial permeability and microbial
translocation. HIV accumulates preferentially within Th17 cells with time on ART; these
memory CD4+ T cells are highly susceptible to HIV infection and are concentrated within the
gut. Vitamin D promotes gut epithelial integrity in animal models and exerts
anti-inflammatory effects on the human immune system including down-modulation of Th17 cell
frequency. This study will evaluate whether high dose vitamin D is able to reduce immune
activation and Th17 cell frequency, to improve gut barrier integrity and the gut microbiome
and reduce HIV persistence in participants on long-term suppressive ART.
Phase:
Phase 2
Details
Lead Sponsor:
University of Melbourne
Collaborators:
Melbourne Health Melbourne Sexual Health Centre National Institute of Allergy and Infectious Diseases (NIAID) The Alfred University of Illinois at Chicago
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins